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sequenced following ampli®cation from the DNA of ten CD patients and two unaffected
individuals. Of 35 identi®ed SNPs, SNP 1±11, selected for their rare-allele frequencies
greater than 0.08, were typed on 1,272 members of the 235 CD families. SNP 12 and 13
were further identi®ed by sequencing the 11 exons of the candidate IBD1 gene in 50 CD
patients (SNP 1±13, GenBank accession numbers G67943±G67955, are submitted to
dbSNP of the National Center for Biotechnology Information) and typed on the same
group of individuals. To search for rare variant alleles, we subsequently investigated the 11
exons of 457 CD patients, 159 ulcerative colitis patients and 103 unaffected unrelated
individuals. All variant alleles were con®rmed by sequencing a second independent
ampli®cation product.
Data analysis
Genotypic data were analysed for linkage using the NPL score of GeneHunter v2.0. Data
from linkage disequilibrium mapping of CD were analysed initially with the transmission
disequilibrium test7 using a single trio (one affected and both parents) per family.
Subsequently, the pedigree disequilibrium test was performed using the PDT 2.11
program8 to analyse data from all family relatives. We estimated allele frequencies for 3
groups, 418 unrelated CD patients, 159 ulcerative colitis patients and 103 controls
(including 78 unaffected, unrelated spouses of CD patients and 25 unrelated CEPH family
members).
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Crohn's disease is a chronic in¯ammatory disorder of the gastro-
intestinal tract, which is thought to result from the effect of
environmental factors in a genetically predisposed host. A gene
location in the pericentromeric region of chromosome 16, IBD1,
that contributes to susceptibility to Crohn's disease has been
established through multiple linkage studies1±6, but the speci®c
gene(s) has not been identi®ed. NOD2, a gene that encodes a
protein with homology to plant disease resistance gene products is
located in the peak region of linkage on chromosome 16 (ref. 7).
Here we show, by using the transmission disequilibium test and
case-control analysis, that a frameshift mutation caused by a
cytosine insertion, 3020insC, which is expected to encode a
truncated NOD2 protein, is associated with Crohn's disease.
Wild-type NOD2 activates nuclear factor NF-kB, making it
responsive to bacterial lipopolysaccharides; however, this induc-
tion was de®cient in mutant NOD2. These results implicate NOD2
in susceptibility to Crohn's disease, and suggest a link between an
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innate immune response to bacterial components and develop-
ment of disease.
The idiopathic in¯ammatory bowel diseases (IBDs), which
include Crohn's disease (CD) and ulcerative colitis, are chronic
disorders of the gastrointestinal tract with unknown aetiology, and
with a combined prevalence of about 150±200 cases per 100,000 in
western countries8,9. Although the aetiology of IBD is unknown, an
abnormal in¯ammatory response directed against enteric micro-
¯ora in a genetically susceptible host has been proposed10. Familial
clustering of disease and studies of twins strongly suggest that IBD,
and in particular CD, is a genetic disorder11. Genome-wide searches
for IBD-susceptibility genes have resulted in the identi®cation of
several loci for CD and/or ulcerative colitis, most notably for CD, in
the pericentromeric region of chromosome 16 (IBD1)1±6.
NOD2 has structural homology with both the apoptosis regula-
tors Apaf-1/Ced-4 and a class of plant disease resistant (R) gene
products7. Like the latter gene products, NOD2 comprises an
amino-terminal effector domain, a nucleotide-binding domain
and leucine-rich repeats (LRRs) (ref. 7). NOD2 has been mapped
to chromosome 16q12 (ref. 7) and is tightly linked to markers
D16S3396, D16S416 and D16S419 (Fig. 1a)Ða site that precisely
overlaps with IBD1 (ref. 1). Given the genomic localization and the
role of NOD proteins in recognizing bacterial components12, we
thought that NOD2 might function as a susceptibility gene for CD.
The 12-exon genomic organization of the NOD2 gene was
determined by aligning the complementary DNA sequence
(AF178930) with one genomic bacterial arti®cial chromosome
(BAC) clone, RPI11-327F22 (AC007728) (Fig. 1a). All coding
exons and ¯anking introns were sequenced in 12 affected indivi-
duals from pure CD families with increased linkage scores at
D16S3396, as well as in 4 case controls. In three CD patients, a
cytosine insertion was observed in exon 11 at nucleotide 3020
(3020insC) (Fig. 1b). 3020insC resulted in a frameshift at the
second nucleotide of codon 1007 (Fig. 1b), and a Leu1007!Pro
substitution in the tenth LRR, followed by a premature stop codon
(Fig. 1c). The predicted truncated NOD2 protein contained 1,007
amino acids instead of the 1,040 amino acids of the wild-type
NOD2 protein (Fig. 1d ).
We used an allele-speci®c polymerase chain reaction (PCR) assay
(Fig. 2) to type 3020insC in IBD families and case controls.
Analysing only one CD patient per independent family, we observed
preferential transmission (Table 1) from heterozygous parents to
affected children of 3020insC (39 transmissions and 17 non-
transmissions; P = 0.0046). Analysing all independent nuclear
families by sib-TDT (ftp://lahmed.stanford.edu/pub/aspex/index.
html), the empirical P value was similar, P = 0.0007. As expected
from linkage studies2,5, no preferential transmission of 3020insC
was observed among families with ulcerative colitis (data not
shown). As 365 of the 416 independent CD families have several
affected individuals, the applicability of these associations to the
more common, sporadic cases requires further study.
Additional support for association to CD was provided by case-
Figure 1 Identi®cation of a frameshift NOD2 mutation in affected individuals from CD
families. a, Physical map of the region of interest at 16q12. Approximate positions of
chromosomal and genetic markers are based on ref. 22. The human genomic BAC clone
RP11-32722 contains the NOD2 gene and markers stSG46415 and SGC32374. The
exon±intron organization of the human NOD2 gene is shown underneath. b, DNA
sequence electropherograms (exon 11) from control and three affected individuals from
CD families. Patients from families 1 and 6 are heterozygous, whereas the patient from
family 7 is homozygous for 3020insC. The cytosine insertion is indicated by an arrow.
c, Nucleotide and predicted amino-acid sequence of exon 11 and ¯anking introns from
wild-type control and patients with 3020Cins. The exon sequence is shown in bold. The
site of 3020insC is indicated by an arrow. Residue (W) indicates that a nucleotide from
exon 12 contributes to the codon. d, Domain structure of NOD2, illustrating the site of
protein truncation. Caspase-recruitment domains (CARDs), the nucleotide-binding
domain (NBD) and ten LRRs are shown. Residues of the tenth LRR are underlined.
Numbers indicate residue positions.
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control analysis, in which, using one CD individual per independent
family, the 3020insC allele frequency among all CD groups was 8.2%
(Table 2). The allele frequencies of 3020insC were comparable
among Jewish (8.4%) and non-Jewish Caucasians (8.1%). Among
case controls (Table 2), the allele frequency in four separate
Caucasian cohorts of 4.0% was signi®cantly lower than in CD
patients (P = 0.0018, by large-sample approximations to a two-
sample binomial test). The allele frequency of the 3020insC among
182 unrelated ulcerative colitis patients was 3.0%, and was signi®-
cantly lower than the frequency among CD patients (P = 0.0010).
The genotype frequencies of 3020insC in unrelated CD individuals
were 11 homozygotes, 46 heterozygotes and 359 wild-type homo-
zygotes.
Among case controls, there were 23 heterozygous individuals,
with the remaining being wild-type homozygotes. The genotype-
relative risk (GRR) for heterozygous and homozygous 3020insC was
1.5 and 17.6, respectively, as compared with wild-type controls.
Given its frequency, 3020insC is unlikely to account completely for
the observed evidence of linkage at IBD1, and other variants of
NOD2 may confer additional disease risk. For example, two single-
nucleotide polymorphisms in NOD2 have been identi®ed, 2722G!
C (Gly908Arg) and 2104C!T (Arg702Trp), which are highly asso-
ciated with CD by the transmission disequilibrium test (data not
shown). Furthermore, other susceptibility genes might also be
present in this broad region1±6 of linkage on chromosome 16.
NOD2 has been shown to activate NF-kB and to confer respon-
siveness to bacterial lipopolysaccharides7,12. To test the ability of
wild-type and mutant NOD2 to activate NF-kB, human embryonic
kidney (HEK) 293T cells were transiently co-transfected with wild-
type or 3020insC plasmids and an NF-kB reporter construct. In the
absence of lipopolysaccharide (LPS), expression of both wild-type
and mutant NOD2 induced activation of NF-kB (Fig. 3a). Notably,
equivalent levels of wild-type and mutant NOD2 protein expression
(as assessed by immunoblotting of total lysates) resulted in similar
levels of NF-kB activation (Fig. 3a).
Like NOD2, cytosolic plant disease resistant proteins have car-
boxy-terminal LRRs that are critical for the recognition of pathogen
components and induction of pathogen-speci®c responses13±15. We
therefore compared the ability of wild-type and mutant NOD2
proteins to induce NF-kB activity in response to LPS. Because
overexpression of NOD2 induces potent NF-kB activation (Fig. 3a),











Figure 2 Determination of transmission of the 3020insC mutation in a CD family by allele-
speci®c PCR. Multiplex PCR was used to generate a nonspeci®c 533-bp product, along
with allele-speci®c amplicons: a 319-bp fragment (wild type) and a 214-bp fragment
(3020insC). In this family, both parents (lanes 1 and 4) are heterozygous for 3020insC,
whereas both children (lanes 2 and 3) have CD and are homozygous for 3020insC. Lane
5, wild-type control; lane 6, pBR322 DNA MspI markers. Numbers on the right indicate
the size of fragments.
Figure 3 Differential responsiveness of wild-type and mutant NOD2 to LPS. a, HEK293T
cells were co-transfected in triplicate with the indicated amounts of pcDNA3 (vector), wild-
type pcDNA3-NOD2, or pcDNA3-NOD2 3020insC and pEF-BOS-b-gal and pBVI-luc
reporter plasmids. Values represent means 6 s.d. Expression of wild-type and mutant
NOD2 proteins in cell extracts is shown on top. b, HEK293T cells were co-transfected in
triplicate with 0.3 ng of pcDNA3-NOD2, 3 ng of pcDNA3-NOD2 3020insC, 3 ng of
pcDNA3-TLR4 plus 3 ng of pcDNA3-MD-2 (indicated by TLR4) or pcDNA3 (vector) and
pEF-BOS-b-gal and pBXIV-luc. Under these conditions, both wild-type and mutant NOD2
constructs induced similar levels of basal NF-kB activity. Eight hours after transfection,
cells were treated with 10 mg ml-1 of LPS from indicated bacteria. Values represent
means 6 s.d. Results are representative of at least ®ve independent experiments.
Table 1 TDT demonstrates preferential transmission of the 3020insC to CD
patients
One CD patient per family All CD patients
Source Transmitted Not
transmitted
P value Transmitted Not
transmitted
.............................................................................................................................................................................
Univ. of Chicago 21 10 32 16
Johns Hopkins 4 4 10 8
Univ. of Pittsburgh 14 3 26 9
Total 39 17 0.0046 68 33
.............................................................................................................................................................................
Table 2 Allele frequency of 3020insC in unrelated Crohn's disease patients
and controls







Univ. of Chicago 212 7.3 Chicago 65 3.8
Johns Hopkins 88 6.8 Baltimore 46 3.2
Univ. of Pittsburgh 116 10.8 San Francisco 81 3.1
Germany 94 5.3
Total 416 8.2 287 4.0
.............................................................................................................................................................................
For analysis, one CD patient was selected from 416 independent families. the difference in allelic
frequency between CD patient and control was signi®cant (P = 0.0018, by the large sample
approximations to a two sample binomial test).
* Per cent allele frequency.
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NOD2 plasmids to induce similar levels of protein expression and
basal NF-kB activity (Fig. 3a). LPS from various bacteria induced
NF-kB activation in cells expressing wild-type NOD2, but not in
cells transfected with control plasmid (Fig. 3b).
Signi®cantly, the ability of mutant NOD2 to confer responsive-
ness to LPS was greatly diminished when compared with wild-type
NOD2 (Fig. 3b). Differential regulation of NOD2 function by LPS
from different bacteria was observed (Fig. 3b), whereas all LPS
preparations induced NF-kB activation comparably in cells trans-
fected with Toll-like receptor-4 (TLR-4), a cell-surface receptor for
LPS16.
The innate immune system regulates the immediate response to
microbial pathogens and is initiated by recognition of speci®c
pathogen components by receptors in host immune cells16. NOD1
and NOD2 seem to function as intracellular receptors for LPS with
the LRRs required for responsiveness12. We have shown here that
truncation of the tenth LRR of NOD2 is associated with CD.
Consistent with earlier linkage studies2,5, this variant is associated
solely with CD, and not with ulcerative colitis. Functional analyses
indicate that the disease-associated NOD2 variant is signi®cantly
less active than the wild-type protein in conferring responsiveness
to bacterial LPS. In plant NOD2 homologues, the LRRs determine
the speci®city for pathogen products and alterations in LRRs can
result in unresponsiveness to particular pathogens13±15. Similarly,
genetic variation in the LRRs of TLR4 account for inter-individual
differences in bronchial responsiveness to aerosolized LPS17.
Several mechanisms can be envisaged to account for susceptibility
to CD in individuals carrying this variant. NOD2 is a cytosolic
protein whose expression is restricted to monocytes, with no
expression detected in lymphocytes7. A de®cit in sensing bacteria
in monocytes/macrophages might result in an exaggerated in¯am-
matory response by the adaptive immune system. A related possi-
bility is that wild-type NOD2 may mediate the induction of
cytokines such as interleukin-10 that can downregulate the in¯am-
matory response18,19. Finally, variation in the LRRs of plant NOD2
homologues can result in recognition of new speci®cities for
pathogen components13,14. Thus, it is also possible that NOD2
variants might act as gain-of-function alleles for unknown patho-
gens. Our studies implicate NOD2 in susceptibility to CD, and
suggest a link between an innate response to bacterial components
and development of disease. M
Methods
IBD families
IBD families were ascertained for linkage and association studies (affected child with both
parents) through the University of Chicago, the Johns Hopkins Hospital and the
University of Pittsburgh. In all cases informed consent for a molecular genetic study was
obtained, and the study protocol was approved by the individual institutional review
boards.
Allele-speci®c PCR
We used primers framing a 533-base-pair region surrounding the 3020insC allele to
amplify genomic DNA isolated from controls and patients by PCR (sense, 59-
CTGAGCCTTTGTTGATGAGC-39; antisense, 59- TCTTCAACCACATCCCCATT-39). In
addition, each PCR reaction contained two additional primers designed to detect the wild-
type allele (sense, 59- CAGAAGCCCTCCTGCAGGCCCT-39) and another primer
designed to detect the 3020insC allele (antisense, 59-CGCGTGTCATTCCTTTCAT
GGGGC-39). The 3020insC was con®rmed by DNA sequencing. We performed multiplex
PCR with all four primers in one tube. PCR products were isolated on 2% agarose gels and
visualized with ethidium bromide.
Data analysis
The P values for the TDT test20 were calculated using a binomial exact test. Simulations
(500,000 replicates) were done using the sib-TDT software (ftp://lahmed.stanford.edu/
pub/aspex/index.html) to calculate empirical probabilities for the TDT x2 statistic when
all independent nuclear families were counted. This calculation was done by permuting
parent alleles while ®xing the IBD status of siblings within a family. We estimated the
frequency of the genotypes in the affected individuals from 416 unrelated CD patients. The
GRRs21 are de®ned as the ratio of the marginal penetrance of the 3020insC homozygote
and heterozygote genotypes to the wild-type homozygotes. Using Bayes rule, the GRRs can
be expressed as a function of the allele frequencies in the case and control groups. For the
control group, we assumed that the alleles are in Hardy±Weinberg equilibrium.
Expression plasmids and immunoblotting
The expression plasmids pcDNA3-NOD2, pcDNA3-TLR4 and pcDNA3-MD-2 have been
described7,12. The expression plasmid producing the NOD2D33 mutant (3020insC) was
generated by PCR and cloned into pcDNA3 (Invitrogen), and con®rmed by DNA
sequencing. Expression of untagged NOD2 proteins in transfected cells was determined by
immunoblotting using af®nity-puri®ed rabbit anti-NOD2 antibody, as described7. To
raise the antibody, we overexpressed recombinant NOD2 protein (residues 28±301) in
Escherichia coli strain BL21(DE3) using the pET-30a vector (Novagen). Recombinant
NOD2 protein containing a C-terminal histidine tag was puri®ed using a nickel column
(Novagen) and injected into rabbits.
NF-kB activation assay
We carried out NF-kB activation assays as described7,12. Brie¯y, HEK293T cells were co-
transfected with 12 ng of the reporter construct pBVI-Luc, the indicated amounts of each
expression plasmid and 120 ng of pEF-BOS-b-gal in triplicate in the presence or absence of
LPS7,12. LPS from various sources were obtained from Sigma or from several investigators.
Twenty-four hours after transfection, cell extracts were prepared and the relative luciferase
activity was measured as described7,12. Results were normalized for transfection ef®ciency
with values obtained with pEF-BOS-b-gal.
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